araag2/HINT huggingface dataset:
Clinical trial NCT00144677 (phase 2, status: completed)
Conditions: acute myelogenous leukemia, graft versus host disease, acute lymphoblastic leukemia, chronic myelogenous leukemia, myelodysplastic syndromes, non-hodgkin's lymphoma, hodgkin's disease
ICD codes: C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01, D89.810, D89.811, D89.813, D89.812, C91.01, C91.02, C91.00, C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01, D46.9, D46.C, D46.Z, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, C81.77, C81.97, C81.17, C81.27, C81.37, C81.47, C81.70
Drugs: sirolimus, tacrolimus
SMILES: CC(=O)CC(C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=CC=C2, COC1=CC2=C(C(OC)=C1OC)C1=CC=C(OC)C(=O)C=C1C(CC2)NC(C)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Acute myelogenous leukemia(AML) in first or subsequent remission, in untreated first
             relapse or any treated relapse.

          -  Acute lymphoblastic leukemia(ALL) in first or subsequent remission, in untreated first
             relapse or any treated relapse.

          -  Chronic myelogenous leukemia in first or second chronic stable phase or in accelerated
             phase.

          -  Myelodysplastic syndromes or myeloproliferative diseases

          -  Non-Hodgkin's lymphoma or Hodgkin's disease in second or greater complete remission,
             in partial remission, or induction failure.

          -  Chronic lymphocytic leukemia, Rai stage 2-4, which has progressed after initial
             therapy.

          -  Matched unrelated donor.

          -  Age 18-55 years at the time of stem cell transplantation

          -  ECOG performance status 0-2

          -  Life expectancy of 100 days without stem cell transplantation

          -  Total bilirubin < 2.0 mg/dl

          -  AST < 90 IU

          -  Serum creatinine < 2.0 mg/dl

          -  Ejection fraction > 40% by echocardiogram or gated nuclear medicine study.

        Exclusion Criteria:

          -  Uncontrolled infection

          -  Forced vital capacity or DLCO < 50% predicted for age

          -  Uncontrolled hypertension

          -  Prior hematopoietic stem cell transplant

          -  Evidence of HIV infection or active Hepatitis B or C infection

          -  Cholesterol > 300 mg/dl

          -  Relapsed aggressive Burkitt's or Burkitt's-like lymphoma
Clinical trial NCT00535847 (phase 2, status: completed)
Conditions: hepatitis c
ICD codes: B18.2, B17.10, B17.11, B19.20, B19.21, B15.0, B15.9
Drugs: telaprevir, ribavirin, pegylated interferon alfa 2a
SMILES: [H][C@@]12CCC[C@]1([H])[C@H](N(C2)C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C1CCCCC1)C(C)(C)C)C(=O)N[C@@H](CCC)C(=O)C(=O)NC1CC1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Enrolled in the control arm of Study VX06-950-106 (NCT00420784), VX05-950-104
             (NCT00336479) or VX05-950-104EU (NCT00372385)
Clinical trial NCT00583128 (phase 2, status: completed)
Conditions: irritable bowel syndrome
ICD codes: K58.2, K58.8, K58.0, K58.1, K58.9
Drugs: ast-120, celphere® cp-305
SMILES: [C]
Eligibility criteria:

        Inclusion Criteria:

          -  Body weight ≥ 40 kg;

          -  Recurrent abdominal pain or discomfort for three or more days per month for the last
             three months which meets Rome III criteria for non-constipating IBS;

          -  Patients on a stable diet for at least eight weeks;

          -  Patients ≥ 50 years of age with a negative screening colonoscopy in the last five
             years;

          -  Able and willing to comply with all protocol procedures for the planned duration of
             the study;

          -  Able and willing to understand, sign and date an informed consent document, and
             authorize access to protected health information,

          -  Females must be postmenopausal, surgically incapable of bearing children, or
             practicing a reliable method of birth control (intrauterine devices, spermicide and
             barrier) (Hormonal contraceptives are NOT regarded as adequate for the purpose of this
             trial.) Partner/spouse sterility may also qualify at the Investigator's discretion.
             Females of child-bearing potential must have a negative urine pregnancy test at
             baseline.

        Exclusion Criteria:

          -  Constipating IBS;

          -  History of untreated lactose intolerance;

          -  History of colonic or major abdominal surgery (colectomy, for example);

          -  Active (untreated) Thyroid disease;

          -  Current diagnosis of major depression or psychosis;

          -  Known positive stool cultures for Clostridium difficile or other pathogens;

          -  Any condition necessitating the administration of analgesics (except paracetamol),
             probiotics, neuroleptics, antidepressants for IBS symptoms, daytime tranquilizers,
             prokinetics or spasmolytic medications;

          -  Poor tolerability of venipuncture or lack of adequate venous access for required blood
             sampling;

          -  Other major physical or major psychiatric illness within the last six months that in
             the opinion of the investigator would affect the patient's ability to complete the
             trial;

          -  Uncontrolled systemic disease such as diabetes;

          -  Patients undergoing chemotherapy for the treatment of cancer;

          -  Known hypersensitivity or contraindication to any component of the test product (study
             drugs) or diagnostics used;

          -  Participation in another study within eight (8) weeks prior to the study;

          -  Unable to attend all visits required by the protocol;

          -  Female patients must be excluded if they are pregnant, breast feeding, or planning to
             become pregnant during the study.
Clinical trial NCT01548404 (phase 2, status: completed)
Conditions: atopic dermatitis
ICD codes: L20.89, L20.9
Drugs: placebo, dupilumab
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CCO
Eligibility criteria:

        Inclusion Criteria:

        The inclusion criteria included, but were not limited to the following:

          1. Male or female, 18 years or older;

          2. Chronic Atopic Dermatitis (AD) for at least 3 years;

          3. History of inadequate response to a stable (>/= 1 month) regimen of topical
             corticosteroids or calcineurin inhibitors as treatment for AD within 3 months before
             the screening visit.

        Exclusion Criteria:

          1. Prior treatment with REGN668;

          2. Presence of certain laboratory abnormalities at the screening visit;

          3. Treatment with an investigational drug within 8 weeks ;

          4. Treatment with a live (attenuated) vaccine within 12 weeks before the baseline visit;

          5. Certain treatments and medical procedures, undertaken within a particular time-frame
             prior to the baseline visit, preclude eligibility for participation in the study;

          6. Known history of human immunodeficiency virus (HIV) infection;

          7. History of malignancy within 5 years before the baseline visit, with certain
             exceptions;

          8. Planned surgical procedure during the length of the patient's participation in this
             study;

          9. History of clinical parasite infection;

         10. Any medical or psychiatric condition which in the opinion of the investigator or the
             sponsor's medical monitor, would place the participant at risk, interfere with
             participation in the study, or interfere with the interpretation of study results;

         11. Pregnant or breast-feeding women.
Clinical trial NCT00183963 (phase 2, status: terminated)
Conditions: breast carcinoma
ICD codes: C4A.52, C44.511, C44.521, D05.00, D05.01, D05.02, D05.10
Drugs: tamoxifen, fulvestrant, fulvestrant
SMILES: OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2, [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(O)C=C3C[C@@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)[C@@]21[H], [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(O)C=C3C[C@@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)[C@@]21[H]
Reason stopped: 
    insufficient accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Postmenopausal women with newly diagnosed DCIS. Women will be considered to be in
             menopause if they fall into one of the following groups:

               -  Age > 60

               -  Age > 45 with amenorrhea > 1 year with intact uterus

               -  Status post bilateral oophorectomies

               -  FSH/estradiol levels in postmenopausal range for the institution

          -  DCIS must have been diagnosed with a minimally invasive biopsy technique, such as a
             vacuum-assisted large core tool (Mammotome) or an equivalent method.

          -  There must be available tissue from the diagnostic biopsy to perform molecular
             markers.

          -  Baseline mammogram within 8 weeks of study entry.

          -  Serum creatinine less than or equal to 2.0 mg/dl.

          -  Total bilirubin less than or equal to 2.0 upper limit of normal (ULN), transaminases
             (SGOT and/or SGPT) and alkaline phosphatase may be up to 2.5 x institutional upper
             limit of normal (ULN), AGC greater than or equal to 1500, platelets greater than or
             equal to 100,000, Hemoglobin greater than or equal to 8.0 g/dl

          -  Peripheral neuropathy grade 0-1.

          -  No prior therapy for DCIS.

          -  SWOG performance status of less than or equal to 1

          -  All patients must provide informed written consent

        Exclusion Criteria:

          -  Prior hormonal therapy (antiestrogens, estrogen, SERM's, progestins, or aromatase
             inhibitors) within 6 months of study entry.

          -  Underlying medical, psychiatric or social conditions that would preclude patient from
             receiving treatment.

          -  History of DVT or Pulmonary Embolism
Clinical trial NCT00267696 (phase 2, status: completed)
Conditions: ovarian cancer, fallopian tube cancer, peritoneal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, C57.00, C57.01, C57.02, K65.1, K66.0, N99.4, N73.6, R88.0, Z49.32, Z49.02
Drugs: bevacizumab, gemcitabine, carboplatin
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, N[C@@H](CCCNC(N)=N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Cancer of the ovaries, fallopian tube or abdominal lining has come back after more
             than 6 months from the last platinum based chemotherapy treatment.

          -  Disease must be detected by CT or CA125 level must be elevated or cancerous ascites
             must be present.

          -  History of at least one therapy of platinum based chemotherapy.

        Exclusion Criteria:

          -  Participation in another experimental drug study

          -  Heart disease or high blood pressure

          -  History of a stroke within the past 6 months

          -  Vascular disease, or bleeding problems

          -  Brain cancer

          -  Major Surgical Procedure within 28 days prior to start date

          -  Minor surgical procedures within 7 days prior to start date

          -  Pregnant or lactating

          -  Abdominal or bowel problems like bleeding

          -  History of abdominal fistula, GI perforation or Intra-abdominal abscess

          -  Serious, non-healing wound, ulcer or bone fracture

          -  Acute hepatitis

          -  Active infections requiring antibiotics

          -  Inability to comply with study or follow up procedures
Clinical trial NCT02716779 (phase 2, status: completed)
Conditions: hepatitis c, chronic
ICD codes: B18.2, B18.0, B18.1, B18.8, B18.9, K71.3, K71.4
Drugs: pegylated interferon (peg-ifn) alfa-2a, placebo, ribavirin
SMILES: CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  Caucasians, male or female aged between 18 and 70 years

          -  Indication: serological proof of a chronic hepatitis C infection with positive result
             of anti-Hepatitis C virus (HCV) test and detectable HCV- Ribo Nucleic Acid (RNA) in
             serum

          -  Proven HCV genotype 1 by means of the reverse hybridization assays

          -  Proven histological infection activity within the liver with or without proven
             compensated cirrhosis within the last 24 months prior to start of the study
             (Child-Pugh degree A)

          -  Participants without previous anti-HCV therapy

        Exclusion Criteria:

          -  Known hypersensitivity to interferon or ribavirin or any of the other component parts

          -  Pregnant or nursing women, women with child bearing potential and without using a high
             effective method of contraception. The urine and serum pregnancy test at visit 0 in
             fertile participants or cohabitants of participants must show a negative result

          -  Male partners of pregnant women

          -  Infection with HCV genotype 2, 3, 4, 5, or 6

          -  Pretreatment with interferon and/or ribavirin

          -  Immunocompromised participants

          -  Treatment of systemic anti-neoplastic or immunomodulatoric medication (including
             supraphysiological doses of steroids or radiation therapy) within the last 6 months
             prior to the start of treatment and during the complete time interval of study
             treatment

          -  Chronic hepatitis due to hepatitis C virus (e.g. haemochromatosis,
             autoimmunohepatitis, metabolic or alcohol-related liver disease)

          -  Decompensated liver cirrhosis or liver disease Child-Pugh degree B or C or condition
             after decompensation

          -  Signs of a hepatocellular carcinoma within 2 months prior to randomization in case of
             a cirrhosis or a transition to cirrhosis

          -  Ascites or esophagus varices with bleedings as documented in anamnesis

          -  Any medical condition that questions in the opinion of the investigator the
             participant's enrollment and participation in the trial

          -  Hemoglobin <13 grams/deciliter (g/dl) in females and <14 g/dl in males in screening
             phase

          -  Patients with an increased anemia risk (e.g. thalassemia, spherocytosis, etc.) or
             patients which would be at a particular medical risk in case of an anemia

          -  Diagnosed neutropenia <1.500/microliter (mcl) or thrombocytopenia <90.000/mcl in
             screening phase
Clinical trial NCT00612586 (phase 2, status: completed)
Conditions: colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: enzastaurin, placebo, leucovorin (lv), 5-fluorouracil (5-fu), bevacizumab (bev)
SMILES: CN1C=C(C2=CC=CC=C12)C1=C(C(=O)NC1=O)C1=CN(C2CCN(CC3=CC=CC=N3)CC2)C2=CC=CC=C12, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H]C(=O)N1C(CNC2=CC=C(C=C2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNC2=C1C(=O)NC(N)=N2, FC1=CNC(=O)NC1=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologic diagnosis of locally advanced or metastatic colorectal cancer (CRC) that is
             not curable. The histology types to be included are adenocarcinoma, mucinous
             adenocarcinoma, signet ring, and undifferentiated. Patients with neuroendocrine
             carcinomas will be excluded.

          -  Received 6 cycles (3 months [12 weeks]) of first-line therapy with FOLFOX or FOLFIRI,
             plus bevacizumab for metastatic CRC. Patients have received at least 5 cycles with
             bevacizumab. Patients who received 6 cycles of first-line therapy with FOLFOX or
             FOLFIRI, plus bevacizumab for recurrent CRC that has relapsed at least 12 months after
             completion of adjuvant therapy will also be included. All standard FOLFOX (FOLFIRI)
             regimens given on a biweekly schedule will be permitted; however, 21-day regimens will
             not be allowed.

          -  No more than 4 weeks may pass between the end of first-line therapy (that is, Day 14
             of Cycle 6) and randomization.

          -  Documented evidence of tumor response of complete response (CR), partial response
             (PR), or stable disease (SD) by computed tomography (CT) scan or magnetic resonance
             imaging (MRI). Confirmation of response is not required.

        Exclusion Criteria:

          -  Are unable to swallow tablets.

          -  Have received treatment within the last 30 days with a drug that has not received
             regulatory approval for any indication at the time of study entry.

          -  Have known central nervous system metastases.

          -  Are receiving concurrent administration of any other antitumor therapy.

          -  Patients who have significant heart, liver, kidney, or psychiatric disease or have an
             active infection
Clinical trial NCT00620113 (phase 2, status: completed)
Conditions: osteoporosis postmenopausal
ICD codes: N95.0, N95.2
Drugs: odanacatib, placebo
SMILES: CC(C)(F)C[C@H](N[C@@H](C1=CC=C(C=C1)C1=CC=C(C=C1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Postmenopausal woman (for at least 5 years) or men who are aged between 45 to 85

          -  Participant who has low bone mineral density

          -  Participant has anatomy suitable for dual-energy x-ray absorptiometry (DXA) of the
             lumber spine and hip

          -  Participant is ambulatory (can walk)

        Exclusion Criteria:

          -  Participant has secondary osteoporosis or has a metabolic bone disorder other than
             osteoporosis or osteopenia

          -  Participant has received osteoporosis medications or other medications that affect
             bone

          -  Participant is already participating in another drug study
Clinical trial NCT00408564 (phase 2, status: completed)
Conditions: pancreatic cancer
ICD codes: C25.3
Drugs: capecitabine, oxaliplatin, gemcitabine
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically or radiologically confirmed pancreatic cancer, meeting both of the
             following criteria:

               -  Locally advanced, nonmetastatic disease

               -  Surgically unresectable disease

          -  Measurable disease, defined as unidimensionally measurable by physical exam or imaging
             study

               -  The following are considered nonmeasurable disease:

                    -  Bone-only disease

                    -  Pleural or peritoneal effusions

                    -  CNS lesions

                    -  Irradiated lesions in the absence of progression after radiotherapy

          -  No history or evidence of CNS disease

          -  No metastatic disease to distant organs (e.g., liver, lung, brain, or bone)

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-2

          -  Granulocyte count ≥ 1,500/mm³

          -  Platelet count ≥ 100,000/mm³

          -  Bilirubin ≤ 2.0 mg/dL

          -  Creatinine ≤ 2.0 mg/dL

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for ≥ 90 days after
             completion of study therapy

          -  No acute hepatitis

          -  No known HIV positivity

          -  No active or uncontrolled infection

          -  No significant history of uncontrolled cardiac disease, including, but not limited to,
             any of the following:

               -  Uncontrolled hypertension

               -  Unstable angina

               -  Myocardial infarction within the past 6 months

               -  Uncontrolled congestive heart failure

               -  Cardiomyopathy with decreased ejection fraction

          -  No prior severe infusion reaction to a monoclonal antibody

          -  No active second malignancy other than nonmelanoma skin cancer

          -  No history of deep vein thrombosis

          -  No history of bleeding diathesis or coagulopathy

          -  No other severe concurrent disease, mental incapacitation, or psychiatric illness that
             would preclude study participation

        PRIOR CONCURRENT THERAPY:

          -  No prior therapy for pancreatic cancer

          -  No prior therapy specifically targeting the epidermal growth factor-receptor pathway

          -  No major surgical procedure or open biopsy within the past 28 days

          -  No prior radiotherapy or chemotherapy

          -  No prior or concurrent full-dose anticoagulants or thrombolytics
Clinical trial NCT01626573 (phase 2, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: itacitinib, itacitinib placebo
SMILES: FC1=C(N=CC=C1C(=O)N1CCC(CC1)N1CC(CC#N)(C1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1)C(F)(F)F, FC1=C(N=CC=C1C(=O)N1CCC(CC1)N1CC(CC#N)(C1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1)C(F)(F)F
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects with active RA aged 18 to 75 years of age and meet tender and swollen joint
             assessment expectations defined in the study protocol.

          -  c-Reactive protein (CRP) or erythrocyte sedimentation rate (ESR) laboratory values
             meet minimal study protocol expectations.

        Exclusion Criteria:

          -  Females who are pregnant or breastfeeding.

          -  Men and women who cannot comply with requirements to avoid fathering a child or
             becoming pregnant, respectively.

          -  Subjects treated with a biologic agent within 12 weeks prior to first dose of study
             drug. (12 months in the case of rituximab.)

          -  Subjects with a history or currently suspected inflammatory disease other than RA.

          -  Subjects with a history of hematological disorders.